Podcasts
In the newest episode of “The Weekly Bioanalysis” podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to translate…
Blogs
Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development. They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or autoreactive…
Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In addition,…
News
KCAS Bio is proud to announce that its EU site (Lyon, France) has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP), confirming its ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. Our GLP test facility was granted a Level of compliance “A”, reinforcing KCAS Bio’s capability to…
Podcasts
In episode #29 of “The Conversational Flow” podcast, our hosts, Brian and Adam, are joined by guests from Accelerating Cancer Immunotherapy Research (ACIR), a nonprofit dedicated to sharing important advances in cancer immunotherapy with the scientific community and the public. Ute Burkhardt discusses her background in cancer vaccines and neoantigen-driven…
Blogs
Reliable immune profiling across global studies depends on methods that perform consistently, regardless of where they are run. We address this question in the white paper entitled “Cross-Site Validation of a 15-Color Spectral Cytometry Panel for Leukocyte Profiling,” documenting a global collaboration between KCAS Bio and its strategic partner,…
Posters & Papers
Discover in this white paper a global collaboration between KCAS Bio and its strategic partner, Crux Biolabs, to harmonize and validate a standardized 15-color spectral flow cytometry panel for pan-leukocyte profiling across multiple sites. If you have any questions about these services or any others offered by…
April 27
- April 28
KCAS Bio will be attending BioVaria in Munich, on April 27-28, 2026. This event connects leading tech transfer professionals and academic innovators with start-ups and representatives from the global biotech and pharma industry. Supporting Biologics Drug Development KCAS Bio supports small and large molecule drug development across preclinical and…
March 26
- March 26
KCAS Bio will be attending Innovation for Health in Utrecht, March 26, 2026. This events brings together key players from the Life Sciences & Health ecosystem. Centered on the theme “Bridging the Gap – From Idea to Innovation & from Patent to Patient,” the conference fosters insight sharing, collaboration, and…
April 21
- April 22
KCAS Bio will be attending German Biotech Days in Leipzig, on April 21–22, 2026. German Biotech Days (DBT) bring together entrepreneurs, scientists, and key partners from across the biotech ecosystem, including investors, funding institutions, policymakers, and public administration. Supporting Biologics Drug Development KCAS Bio supports small and large molecule…
March 24
- March 25
KCAS Bio will be attending NextGen Biomed 2026 in London, on March 24–25, 2026. NextGen Biomed is a long-standing, community-driven platform that brings together the biologics and immunotherapy ecosystem to foster interdisciplinary collaboration and knowledge sharing across the R&D lifecycle. Supporting Biologics Drug Development KCAS Bio supports biologics drug…
Podcasts
In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi…